論文 - 詳細
| RRC ID | 67416 |
|---|---|
| 著者 | Yamaguchi A, Usami K, Shimabe M, Hasegawa K, Asada M, Motoki K, Tahara T, Masuda K. |
| タイトル | The novel CA IX inhibition antibody chKM4927 shows anti-tumor efficacy in vivo. |
| ジャーナル | Anticancer Res |
| Abstract |
Carbonic anhydrase IX (CA IX) is an attractive target for cancer therapy. Many anti-CA IX antibodies have been reported but few have been shown to possess inhibition activity. Furthermore, effective use of CA IX-inhibition antibodies for cancer immunotherapy has not been well-validated since data are mainly limited to in vitro assays. In this study, we established that chKM4927, an anti-CA IX chimeric antibody, recognizes CA IX and has CA IX-specific inhibition activity. ChKM4927 also retains antibody-dependent cellular cytotoxicity (ADCC) activity against CA IX-expressing cancer cells. Compared to controls, chKM4927 treatment (10 mg/kg) showed anti-tumor activity in the VMRC-RCW xenograft model in vivo. ChKM4927-attenuated ADCC activity showed equally effective anti-tumor activity. These results suggest that the CA IX-inhibition antibody chKM4927 has an anti-tumor effect in the VMRC-RCW xenograft model via an ADCC-independent mechanism. |
| 巻・号 | 35(4) |
| ページ | 1997-2004 |
| 公開日 | 2015-4-1 |
| PII | 35/4/1997 |
| PMID | 25862852 |
| MeSH | Antibodies, Monoclonal / administration & dosage* Antibody-Dependent Cell Cytotoxicity / immunology Antigens, Neoplasm / immunology* Antigens, Neoplasm / therapeutic use Carbonic Anhydrase IX Carbonic Anhydrases / immunology* Carbonic Anhydrases / therapeutic use Cell Line, Tumor Enzyme Inhibitors / administration & dosage* Enzyme Inhibitors / immunology Humans Molecular Targeted Therapy Neoplasms / immunology Neoplasms / pathology Neoplasms / therapy* Xenograft Model Antitumor Assays |
| IF | 1.994 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 3 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | OS-RC-2(RCB0735) |